Nasdaq auph.
Nov 29, 2023 · 2 analysts have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View analysts price targets for AUPH or ...
Find real-time AUPH - Aurinia Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Find real-time AUPH - Aurinia Pharmaceuticals Inc stock quotes,...(NASDAQ: AUPH) Aurinia Pharmaceuticals currently has 143,608,164 outstanding shares. With Aurinia Pharmaceuticals stock trading at $8.23 per share, the total value of Aurinia Pharmaceuticals stock (market capitalization) is $1.18B .View Inc. (NASDAQ:VIEW) has a beta value of 0.59 and has seen 11.47 million shares traded in the recent trading session. The company, currently valued at $6.84M, closed the recent trade at $1.68 per share which meant it gained $0.65 on the day or 63.11% during that session. ... Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a …Swiss National Bank raised its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 7.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).The firm owned 279,300 shares of the biotechnology company’s stock after acquiring an …
msn.com - August 8 at 2:56 PM. Jump Financial LLC Takes $366,000 Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) marketbeat.com - August 8 at 5:21 AM. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) to Post Q1 2024 Earnings of ($0.14) Per Share, Leerink Partnrs Forecasts. marketbeat.com - August 7 at 7:47 AM.Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week.
On November 2, 2023, Aurinia Pharmaceuticals Inc ( NASDAQ:AUPH) released its financial results for the third quarter and nine months ended September 30, 2023. The company reported a significant ...
Aurinia Pharmaceuticals (NASDAQ:AUPH) is a company that specializes in developing treatments for diseases that currently have few treatment options. They focus on autoimmune, kidney, and rare ...The FDA is scheduled to rule on Aurinia Pharmaceuticals Inc's (NASDAQ:AUPH) voclosporin as a treatment option for lupus nephritis. SHARE THIS POST. FACEBOOK. TWITTER. EMAIL. COPY LINK.Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders Insiders own 2.02% of the company shares, while shares held by institutions stand at 60.74% with a share float percentage of 61.99%. Investors are also buoyed by the number of investors in a company, with Aldeyra Therapeutics Inc having a total of 142 institutions that hold shares in the ...Dec 4, 2023 · Year-to-date, Rivian Automotive Inc shares have moved -4.45%, while the 5-day performance has seen it change 5.70%. Over the past 30 days, the shares of Rivian Automotive Inc (NASDAQ:RIVN) have changed 0.11%. Short interest in the company has seen 103.62 million shares shorted with days to cover at 2.62. Wall Street analysts have a consensus ...
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has seen a decrease in hedge fund interest in recent months. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was in 24 hedge funds' portfolios at the end of ...
Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical …
Find the latest Financials data for Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.See historical performance and comparison. View Valuation. Research Aurinia Pharmaceuticals' (Nasdaq:AUPH) stock price, latest news & stock analysis. Find …Jan 5, 2023 · Aurinia Pharmaceuticals (NASDAQ:AUPH) recently announced they have reached a settlement with Sun Pharmaceuticals (OTCPK:SMPQY) to dismiss their claims and counterclaims against each other. The FDA is scheduled to rule on Aurinia Pharmaceuticals Inc's (NASDAQ:AUPH) voclosporin as a treatment option for lupus nephritis. SHARE THIS POST. FACEBOOK. TWITTER. EMAIL. COPY LINK.
Mar 9, 2023 · 9.24. +0.64. +7.44%. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter ... SVB Leerink waxed optimistic on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), saying the stock could rally 250% if late-stage trial data for the company's kidney inflammation treatment shows a ...Jan 8, 2022 · With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) future prospects. Aurinia Pharmaceuticals Inc., a ... Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right individual stocks, you could make more than that. …The Company’s common shares will no longer be traded on the TSX but will continue to trade on the Nasdaq Capital Market (Nasdaq) under the symbol AUPH. Trading on the Nasdaq accounted for ...T2 Biosystems, Inc. Common Stock. $0.2229 +0.002. Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US ...
Total cost of sales and operating expenses for the quarter ended September 30, 2023 was $70.8 million and $65.3 million for the quarter ended September 30, 2022. Total cost of sales and operating ...Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors. Dr. Karen Smith and Jeffrey A. Bailey joined the board of directors of the Company effective August 18, 2023, bringing with them decades of combined leadership experience in the ...
Nasdaq Auph, also known as Aurinia Pharmaceuticals, is a biopharmaceutical company that focuses on developing and commercializing therapies to treat autoimmune diseases. With a strong pipeline of innovative drugs and a commitment to improving patients’ lives, Nasdaq Auph has garnered attention from investors and industry experts alike.Jun 16, 2023 · Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a good speculative biotech play to look into. That's because it already has received FDA approval of LUPKYNIS™ as an oral treatment for adult ... Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include stock option expenses where possible. Nasdaq provides visual representation of analyst expected ...Anyone who held Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) over the last year knows what a loser feels like. The share price has slid 66% in that time. The share price has slid 66% in that time.Anyone who held Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) over the last year knows what a loser feels like. The share price has slid 66% in that time. The share price has slid 66% in that time.Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Nov. 20, 2023, 12:38 PM. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the ...During the last session, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares were 2.07 million, with the beta value of the company hitting 1.26. At the end of the trading day, the stock’s price was $8.64, reflecting an intraday gain of 0.47% or $0.04. The 52-week high for the AUPH share is ...The company has $337.90 million in cash and $93.21 million in debt, giving a net cash position of $244.69 million or $1.70 per share. Cash & Cash Equivalents.
AUPH Latest After Hours Trades. Select time range to see more trades: Last 100 Trades. After Hours Time (ET) After Hours Price. After Hours Share Volume. 19:59:23. $9.37. 100.
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest ...Jul 18, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ... Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.NASDAQ:AUPH. Press Releases. May 17, 2023. Aurinia Announces 2023 Annual General Meeting Results May 09, 2023. Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.The fact that multiple Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When ...AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis.Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
Nov. 20, 2023, 12:38 PM. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the ...At Aurinia, we embrace the possibility to change the trajectory of autoimmune diseases with unmet needs. With a growing pipeline and a dynamic team of proven experts, our work is patient-centric and driven by a sense of urgency. See how we are poised to deliver on our mission. Learn More.What happened. Shares of the autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) are poised for a tough session today. Ahead of the opening bell, the drugmaker's share price ...Instagram:https://instagram. best platform for algo tradingbest real estate crowdfunding for non accredited investorsvatican news pope francisblnk stock forecast Nasdaq Auph, also known as Aurinia Pharmaceuticals, is a biopharmaceutical company that focuses on developing and commercializing therapies to treat autoimmune diseases. With a strong pipeline of innovative drugs and a commitment to improving patients’ lives, Nasdaq Auph has garnered attention from investors and industry experts alike.Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is a speculative stock and it's not making any money, said Cramer. He prefers Nokia (NYSE:NOK) over Ericsson (NASDAQ:ERIC). how to start investing in arthow can i buy brics currency AUPH Aurinia Pharmaceuticals Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... This section uses the official NASDAQ-supplied short interest and provides some value-added metrics, calculated daily. Short Interest is updated twice monthly on set schedule, but float and shares outstanding are on a different update ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17. soundhound ai inc SVB Leerink waxed optimistic on Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), saying the stock could rally 250% if late-stage trial data for the company's kidney inflammation treatment shows a ...As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.